CLASS I ONGOING Drug recall · Reported 29 Jul 2026 · FDA Enforcement Report

Cetirizine Hydrochloride Tablets USP 5 mg recalled by JB Chemicals and

JB Chemicals and Pharmaceuticals is recalling Cetirizine Hydrochloride Tablets USP 5 mg, distributed nationwide in the US. The recall was initiated on 24 Jun 2026 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesLots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
NDC16571-401
Quantity recalled34,020 100-count bottles.

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0732-2026
FDA event ID
99321
Recalling firm
JB Chemicals and Pharmaceuticals, Mumbai, N/A
Manufacturer
Rising Pharma Holdings, Inc.
Classification
Class I
Status
Ongoing
Recall initiated
24 Jun 2026
FDA classified
3 Aug 2026
Reported
29 Jul 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

24 Jun 2026Recall initiated by company
29 Jul 2026Published in enforcement report+35 days
3 Aug 2026Classified by FDA+5 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Product as listed by the FDA

Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Cetirizine Hydrochloride Tablets USP 5 mg recalled?

Yes. JB Chemicals and Pharmaceuticals recalled Cetirizine Hydrochloride Tablets USP 5 mg on 24 Jun 2026. The recall is Class I and its status is Ongoing. Recall number D-0732-2026.

Why was it recalled?

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Which lots are affected?

Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from JB Chemicals and Pharmaceuticals

All 4
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIEnalapril Maleate Tablets, USP, 20 mg recalled by JB Chemicals andEnalapril MaleateJB Chemicals and PharmaceuticalsPotency & AssayNationwide
DrugCLASS IIICetirizine Hydrochloride Tablets USP 10 mg recalled by JB Chemicals andCetirizine HydrochlorideJB Chemicals and PharmaceuticalsOtherNationwide
DrugCLASS IIICetirizine Hydrochloride Tablets USP 10 mg recalled by JB Chemicals andCetirizine HydrochlorideJB Chemicals and PharmaceuticalsOtherNationwide

Other Cetirizine recalls

All 15